Distribution of CYP2C19 Gene Polymorphisms and Analysis of Antiplatelet Therapy Regimens in 336 Patients undergoing Percutaneous Coronary Intervention for Coronary Artery Disease
Distribution of CYP2C19 Gene Polymorphisms and Analysis of Antiplatelet Therapy Regimens in 336 Patients undergoing Percutaneous Coronary Intervention for Coronary Artery Disease
Objective:Objective to investigate the distribution of CYP2C19 gene polymorphism and the choice of individualized antiplatelet therapy in patients with coronary heart disease undergoing percutaneous coronary intervention(PCI),and to analyze the compliance of doctors in formulating antiplatelet therapy according to the guidelines.Method:A total of 336 patients with acute coronary syndrome who underwent PCI and CYP2C19 gene polymorphism testing in the cardiovascular department between January 2021 and December 2021 were selected as the study subjects.Collect general clinical data of patients,CYP2C19 genotype,and postoperative use of antiplatelet drugs,Analyze whether doctors develop personalized antiplatelet therapy plans based on CYP2C19 genotype.Result:There were 150 patients with CYP2C19 fast metabolism type(44.64％),152 patients with intermediate metabolism type(45.24％),and 34 patients with slow metabolism type(10.12％).76 cases(50.67％)of patients with fast metabolism type were treated with clopidogrel 75mgqd combined regimen,and 74 cases(49.33％)were treated with ticagrelor 90mgbid combined regimen.64 patients(42.1％)of intermediate metabolic type were treated with clopidogrel 75mgqd regimen,and 88 patients(57.89％)were treated with ticagrelor 90mgbid regimen.10 cases(29.41％)of patients with slow metabolism type were treated with clopidogrel 75mgqd combined regimen,and 24 cases(70.59％)were treated with ticagrelor 90mgbid combined regimen.Conclusion:In patients with intermediate metabolism and slow metabolism,doctors have poor compliance with the guidelines for developing antiplatelet regimens based on CYP2C19 test results.Therefore,medication guidance should be strengthened to promote rational clinical use.
维普
万方数据